文献速递妇科

二线奥拉帕利维持治疗与BRCA1/2突变上皮性卵巢癌后续化疗反应差相关:一项多中心回顾性研究

Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study.
PubMed 文献 · Gynecol Oncol · 2022-02-10

该多中心回顾性观察研究纳入2012年1月至2020年6月在韩国三家机构接受二线铂类化疗的BRCA1/2突变上皮性卵巢癌患者197例,奥拉帕利维持组105例,对照组92例。奥拉帕利组PFS2-PFS1较对照组显著缩短(中位7.9 vs 13.6个月,p=0.0005),排除对照组交叉接受三线PARPi维持者后差异仍存在(中位7.7 vs 11.5,p=0.0422),提示奥拉帕利耐药可能 contribute to 化疗耐药。

要点

  • 奥拉帕利组二线后至三线进展间隔较对照组显著缩短(中位7.9 vs 13.6个月,p=0.0005)。
  • 排除对照组交叉接受三线PARPi维持者后,奥拉帕利组后续治疗反应仍差(中位7.7 vs 11.5,p=0.0422)。
  • 铂敏感BRCA1/2突变患者在奥拉帕利维持期间进展后对三线化疗反应较差,提示奥拉帕利耐药可能 contribute to 化疗耐药。

核心结论

  • 二线化疗后接受奥拉帕利维持治疗的BRCA1/2突变上皮性卵巢癌患者,在奥拉帕利维持期间进展后对三线化疗的反应较未接受奥拉帕利者差,提示奥拉帕利耐药可能 contribute to 化疗耐药。

研究设计与样本

  • 多中心回顾性观察研究,纳入2012年1月至2020年6月在韩国三家机构接受二线铂类化疗的BRCA1/2突变上皮性卵巢癌患者197例。
  • 奥拉帕利组为二线化疗后接受奥拉帕利维持治疗者105例,对照组为未接受奥拉帕利维持治疗者92例。
  • 主要终点为第二次疾病进展日期至第三次疾病进展日期的时间间隔,即PFS2-PFS1。

主要发现

  • 奥拉帕利组PFS1较对照组延长。
  • 奥拉帕利组PFS2-PFS1较对照组显著缩短(中位7.9 vs 13.6个月,p=0.0005)。
  • 排除对照组中交叉接受三线PARPi维持治疗的患者后,奥拉帕利组后续治疗反应仍差(中位7.7 vs 11.5,p=0.0422)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: With expanded use of poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi), there is a potential impact of PARPi resistance on platinum resistance. A post-hoc analysis of SOLO2 demonstrated a reduction in response to subsequent platinum-based therapy among patients who received prior olaparib but not placebo. The present multicentre, retrospective, observational study was conducted to determine the effects of olaparib on subsequent therapy for recurrent epithelial ovarian cancer (EOC). MATERIALS AND METHODS: Data on EOC patients with BRCA1/2-mutated tumours who received second-line platinum-based chemotherapy between January 2012 and June 2020, at three South Korean institutions (n = 197) were collected. Patients who received olaparib as maintenance therapy after second-line chemotherapy were assigned to the olaparib group (n = 105), and subjects who did not receive olaparib maintenance therapy were assigned to the control group (n = 92). The primary endpoint was time intervals from the date of second disease progression (PFS1) to the date of third disease progression (PFS2), expressed as PFS2 - PFS1. RESULTS: As expected, PFS1 in the olaparib group was longer than the control group. However, PFS2 - PFS1 in the olaparib group was significantly shorter than that of the control group (median 7.9 vs. 13.6 m; p = 0.0005). Even when the third-line PARPi maintenance (cross-over) patients were excluded from the control group, the response to subsequent therapy in the olaparib group remained poor (median 7.7 vs. 11.5; p = 0.0422). DISCUSSIONS: Patients with platinum-sensitive BRCA1/2 mutated tumours who progressed during olaparib maintenance after second-line chemotherapy were less likely to respond to third-line chemotherapy compared to controls who did not receive olaparib, suggesting that resistance to olaparib may contribute to chemotherapy resistance.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Park J, Kim SI, Jeong SY, et al. Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study. Gynecol Oncol. 2022. PMID: 35153073. doi:10.1016/j.ygyno.2022.02.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。